- 45mg and In severe cases. – ustekinumab patients patients in two doses and involved only two subcutaneous injections over the 12 – week period ED Treatment . A 75 percent improvement in symptoms was observed in 67.5 percent of 45 mg 45 mg dose, and 73.8 percent of the 90 mg dose.
Etanercept, such as Enbrel, Amgen / Wyeth is marketed acts by blocking the action of a chemical signal as TNF? That is involved in the body’s immune response. Ustekinumab, a drug as Stelara by Centocor Research and Development, a marketing subsidiary of Johnson & Johnson aims involved, in two chemical signals in the immune response, cytokines cytokines.